Phenyl Propionic Acid Derivatives as GPR40 Agonists for Glucose Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Type 2 diabetes mellitus (T2DM) have limitations such as side effects like diarrhea, abdominalgia, dyspepsia, liver safety concerns, cardiovascular risks, and limited efficacy, necessitating the development of novel medications that can effectively lower blood glucose levels without risking hypoglycemia.
Innovation Solution
Development of novel phenyl propionic acid derivatives and their pharmaceutically acceptable salts that act as GPR40 agonists, which are orally available and induce glucose-dependent insulin secretion, thereby effectively treating T2DM without the risks associated with existing treatments.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If Metformin is used to treat T2DM, then blood glucose control is improved, but gastrointestinal side effects (diarrhea, abdominalgia, dyspepsia) occur
Solution Approach 1:
The patent changes the mechanism of action parameter from Metformin's AMPK activation to GPR40 agonism, which selectively targets pancreatic beta cells to stimulate insulin secretion only in response to elevated blood glucose, thereby avoiding the gastrointestinal side effects associated with Metformin while maintaining effective blood glucose control
2Reliability
If Sulfonylureas are used to stimulate pancreatic beta cells, then insulin secretion is improved, but hypoglycemia risk increases
Solution Approach 1:
The patent introduces dynamic glucose-dependent insulin secretion through GPR40 agonism, where the insulin secretion response is dynamically adjusted based on blood glucose levels - stimulating secretion when glucose is elevated and avoiding secretion when glucose is normal, thereby maintaining effective insulin secretion while eliminating hypoglycemia risk
Solution Approach 2:
The patent implements a feedback mechanism where GPR40 activation by glucose leads to insulin secretion that subsequently lowers blood glucose, creating a negative feedback loop that automatically regulates insulin secretion according to physiological needs and prevents hypoglycemia
3Reliability
If thiazolidinediones are used for T2DM treatment, then insulin sensitivity is improved, but liver safety concerns and cardiovascular risks arise
Solution Approach 1:
The patent changes the therapeutic approach from improving insulin sensitivity in peripheral tissues (thiazolidinediones) to directly stimulating insulin secretion from pancreatic beta cells via GPR40 agonism, achieving effective blood glucose control through a different physiological parameter that avoids liver and cardiovascular side effects
4Reliability
If SGLT-2 inhibitors are used to lower blood glucose, then blood glucose control is improved, but urinary tract and genital infections increase
Solution Approach 1:
The patent changes the mechanism from renal glucose excretion (SGLT-2 inhibition) to pancreatic insulin secretion stimulation (GPR40 agonism), achieving blood glucose control through endogenous insulin production rather than urinary glucose loss, thereby avoiding the infection risk associated with glucosuria
Data Source
AI summary
Compounds of Formula (I), racemates, enantiomers, diastereomers thereof or pharmaceutical acceptable salts thereof, or pharmaceutical compositions containing the compounds, racemates, enantiomers, diastereomers thereof are disclosed. These compounds have GPR40 agonist activity and are capable of modulating blood glucose levels and glucose-dependent insulin secretion mechanism, and, thus, exhibit excellent glucose lowering efficacy without the risk of hypoglycemia. These compounds could be used in preventing and/or treating type 2 diabetes through adequate control of blood glucose.